• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.28% Nasdaq Up0.07%

    More On TBGNF

    Quotes

    Charts

    News & Info

    Company

    Analyst Coverage

    • Analyst Opinion
    • Analyst Estimates

    Ownership

    • Major Holders
    • Insider Transactions
    • Insider Roster

    Financials

    • Income Statement
    • Balance Sheet
    • Cash Flow

    ThromboGenics NV (TBGNF)

    -Other OTC
    5.39 0.00(0.00%) Jul 14
    Add to Portfolio
    ProfileGet Profile for:
    ThromboGenics NV
    Gaston Geenslaan 1
    Leuven, 3001
    Belgium - Map
    Phone: 32 1 675 13 10
    Fax: 32 1 675 13 11
    Website: http://www.thrombogenics.com

    Details 
    Index Membership:N/A
    Sector:N/A
    Industry:N/A
    Full Time Employees:120

    Business Summary 

    ThromboGenics NV, an integrated biopharmaceutical company, develops and commercializes ophthalmic and oncology medicines in Belgium and internationally. The company’s lead product is JETREA used for the treatment of symptomatic vitreomacular adhesion and vitreomacular traction. It has research and development agreements with BioInvent International AB to develop Anti-PlGF, a product candidate to treat various disorders, such as cancer, age-related macular degeneration, retinopathy, and inflammation; Eleven Biotherapeutics and Bicycle Therapeutics to develop and commercialize products for the treatment of eye diseases with diabetics; and Chilltern International, Inc. and Outcome Sciences, Inc. to provide clinical research services for the development of JETREA. The company was founded in 1991 and is headquartered in Leuven, Belgium.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on ThromboGenics NV

    Key Executives 
     PayExercised
    Dr. Patrik De Haes ViBio, BVBA,
    Chief Exec. Officer and Exec. Director
    781.00KN/A
    Mr. Luc Philips BVBA, 64
    Exec. Director and Member of Audit Committee
    0.00N/A
    Mr. Paul G. Howes , 61
    Exec. Director
    0.00N/A
    Mr. Dominique Vanfleteren ,
    Chief Financial Officer
    N/AN/A
    Mr. Claude Sander ,
    Corp. Compliance Officer and Gen. Counsel
    N/AN/A
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.